rebioin journal
OF BIOSCIENCES

ANTIBIOTIC RESISTANCE IN BACTERIA: MECHANISMS, CAUSES, GLOBAL IMPACT, AND FUTURE STRATEGIES

admin@reboin.com

www.rebioin.com

Antibiotic Resistance in Bacteria: Mechanisms, Causes, Global Impact, and Future Strategies

Ruby Deshwal[1*], Baanipreet Kaur[2], Chanchal[3], Rajesh Kumar[4]

[1]Department of Biotechnology, Chaudhary Charan Singh University, Meerut, UP, India

[2]Department of Biotechnology, Jaypee Institute of Information Technology, Noida, UP, India

[3]Department of Biotechnology, Gautam Buddha University, Greater Noida, UP, India

[4]Rapture Biotech International (P) Ltd., Noida, UP, India

*Corresponding author's Email: deshwalruby65@gmail.com

Abstract

Antibiotic resistance has emerged as a serious threat to global public health, compromising the effective treatment of bacterial illnesses and undermining decades of medical progress. Because of the widespread abuse and overuse of antimicrobial drugs in human health, veterinary practice, agriculture, and environmental systems, resistant bacteria have evolved sophisticated methods to evade antibiotic action. This review offers a thorough analysis of the evolution of antibiotic resistance, following its historical and evolutionary roots from naturally existing resistance mechanisms to the current post-antibiotic age. The key molecular mechanisms underlying resistance, including enzymatic drug inactivation, target site modification, reduced membrane permeability, and active efflux systems, are thoroughly discussed, with a focus on their role in the emergence of multidrug-resistant, extensively drug-resistant, and pan-drug-resistant bacterial strains. Antibiotic resistance's disproportionate effects on low- and middle-income nations, higher healthcare expenditures, longer hospital stays, and risks to cutting-edge medical procedures are all highlighted in this critical analysis of the worldwide health and economic burden of antibiotic resistance. A One Health framework is used to assess current antibiotic resistance control and prevention efforts, including surveillance systems, antimicrobial stewardship programs, infection prevention measures, and regulatory regulations. Furthermore, bacteriophage therapy, antimicrobial peptides, antivirulence tactics, probiotics, nanotechnology-based delivery systems, and combination therapies are investigated as potential ways to combat resistance and prolong the half-lives of current antibiotics. In order to reduce antibiotic resistance and protect the future of efficient antimicrobial therapy, this study highlights the critical need for concerted international action, ongoing research funding, and integrated policy implementation.

Keywords: Antibiotic resistance, Molecular mechanisms, Multidrug resistance, Alternative therapeutics, Alternative antimicrobial therapies; Global health impact.

1. Introduction

Every year, widespread antibiotic resistance among bacteria kills hundreds of thousands of people. It is emerging as one of the most serious dangers to global public health in the twenty-first century. Since Alexander Fleming discovered penicillin in 1928 and the subsequent "golden age" of antibiotic development, antimicrobial medicines have significantly reduced morbidity and death from infectious diseases. However, the extensive and frequently indiscriminate use of antibiotics in human health, veterinary practice, agriculture, and aquaculture has expedited the creation and spread of antibiotic-resistant bacteria, compromising the effectiveness of these life-saving medications [1,2]. According to recent estimates, antimicrobial resistance (AMR) contributed to about 5 million fatalities worldwide in 2019 and was directly responsible for about 1.27 million deaths, with low- and middle-income nations being disproportionately affected [3]. In addition to the high costs of antibiotic research and development, the rapid evolution of AMR has resulted in reduced investment returns for the pharmaceutical R&D industry. Several pharmaceutical companies have already abandoned antibiotic research and the creation of novel medicines. Bacterial resistance to antibiotics was already known more than 50 years ago, because, by the late 1950s, most isolates of S. aureus gained resistance to penicillin, which was previously used to treat them [4]. Nonetheless, for a long time, antibiotic resistance was not a serious worry internationally since, in the 1960s, new classes of antibiotics were produced, such as vancomycin and methicillin, which suggested that the problem of resistance could be readily overcome by the production of new molecules.

A complex web of interrelated factors causes antibiotic resistance. Inappropriate prescription practices, patient non-compliance, the availability of antibiotics over-the-counter in some areas, the widespread use of antimicrobials as growth promoters in livestock, and insufficient infection prevention and control methods are important contributing factors [5]. Bacteria employ a range of molecular strategies to evade the effects of antibiotics, including enzymatic drug inactivation, alteration of antibiotic targets, decreased membrane permeability, and active efflux of antimicrobial drugs. Clinical management is severely hampered by the formation and persistence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) strains of bacteria due to their quick adaptation and the selection pressure caused by antibiotic exposure [6]. Comprehensive efforts to address antibiotic resistance are desperately needed, given the alarming rate at which resistance is growing and the diminishing pipeline of innovative treatments. Programs for antimicrobial stewardship, enhanced surveillance systems, the creation of novel medicines and alternative treatments, better diagnostics, immunization tactics, and international policy cooperation are some of these [7].

1.1 Development of Antibiotic Resistance: Historical Perspective

Antibiotic resistance is a problem that has its roots in microbial evolution and predates the use of antibiotics in clinical settings. Bacteria had developed defense mechanisms against naturally occurring antibiotics made by rival microbes in the environment long before contemporary antimicrobial drugs were discovered. Resistance genes have been found in ancient permafrost and cave microbiota by genomic analysis, indicating that resistance is an inherent aspect of microbial ecology rather than a completely contemporary occurrence.[8] The discovery of penicillin in 1928 marked the start of the modern antibiotic era, but resistance was noted soon after it was widely used in clinical settings in the

1940s [9,10]. During the mid-20th century, the rapid introduction of new antibiotics was accompanied by the emergence of resistant pathogens, including multidrug-resistant *Mycobacterium tuberculosis*. The discovery of plasmid-mediated resistance in the 1950s revealed the role of horizontal gene transfer in accelerating the spread of resistance [11]. The emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) further highlighted the adaptive capacity of bacteria [12]. By the late 20th century, extensive antibiotic use in human medicine and agriculture had intensified selective pressure, leading to widespread resistance and significant public health challenges [13]. The historical development of antibiotic resistance underscores its inevitability and emphasizes the need for antimicrobial stewardship, surveillance, and sustained innovation in antibiotic development. Figure 1 shows the timeline of the development of Antibiotic Resistance.



Figure 1: Timeline of development of Antibiotic Resistance.

1.2 Molecular mechanisms of Antibiotic resistance

Antibiotic resistance is the bacteria's ability to adopt different molecular strategies that allow them to escape the effects of antimicrobial drugs and continue to grow. One of the most widespread strategies involves the inactivation of the drug. In this process, bacteria synthesize specific enzymes, that is, β-lactamases, which break down β-lactam antibiotics, thereby eliminating their antibacterial activity. This process entails the bacterial synthesis of β-lactamase enzymes, which hydrolyze the β-lactam ring, a structural element necessary for these medications' antibacterial action. The antibiotic is unable to stop the formation of bacterial cell walls once this ring is broken because it can no longer attach to its target, the penicillin-binding proteins (PBPs). β-lactamases function at the molecular level by accelerating the nucleophilic assault on the β-lactam ring's amide bond. The genes that encode β-lactamases are often found on integrins, transposons, or plasmids. This allows for quick horizontal transfer between bacterial species and speeds up the spread of resistance in both community and hospital settings [14]. Modification of antibiotic target sites, where

genetic mutations or chemical changes take place in bacterial components such as ribosomal subunits or penicillin-binding proteins, is another crucial resistance tactic. The antibiotic's therapeutic impact is greatly diminished by these structural alterations, which impair the antibiotic's capacity to bind [15]. Additionally, bacteria use efflux pump systems, which actively remove antibiotics from the cell to reduce intracellular drug concentrations below fatal levels. These pumps can confer multidrug resistance or be specific to a single drug [16]. Furthermore, decreased membrane permeability, especially in Gram-negative bacteria, restricts the entry of antibiotics because porin proteins are altered or lost [17]. Resistance genes responsible for these mechanisms are typically acquired through horizontal gene transfer, which includes conjugation, transformation, and transduction, allowing resistance to spread rapidly throughout bacterial populations. Figure 2 shows the mechanism of Antibiotic Resistance [18]. The persistence and worldwide spread of antibiotic-resistant bacteria are mostly caused by these molecular modifications, which pose a serious risk to public health.



Fig. 2: Mechanism of Antibiotic Resistance.

Table 1 shows the Antibiotic Resistance Profiles of Key Pathogenic Bacteria. The table presents a comparative overview of the most clinically relevant bacterial infections, emphasizing the diversity of resistance types, underlying molecular mechanisms, and antibiotic classes rendered ineffective. Gram-positive pathogens like *Enterococcus faecium* (VRE) and *Staphylococcus aureus* (MRSA) show resistance mainly through target modification, such as modified cell wall precursors and altered penicillin-binding proteins (PBP2a encoded by mecA), which result in decreased susceptibility to vancomycin and β-lactams, respectively. The effectiveness of penicillin, cephalosporins, and carbapenems is significantly compromised by Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae, which exhibit enzymatic resistance through extended-spectrum β-lactamases (ESBLs) and carbapenems. Opportunistic pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii display multidrug or

extensive drug resistance mediated by a combination of efflux pump overexpression, porin loss, enzymatic degradation, and target site mutations, limiting treatment options to last-resort antibiotics. Mycobacterium tuberculosis develops multidrug resistance through chromosomal mutations in critical drug targets such as rpoB and katG, conferring resistance to first-line agents isoniazid and rifampicin. Sexually transmitted and foodborne pathogens, including Neisseria gonorrhoeae and Salmonella enterica, rely on enhanced efflux systems and plasmid-mediated resistance determinants, resulting in high-level resistance to fluoroquinolones and other commonly used antibiotics. Collectively, this table underscores the complexity and pathogen-specific nature of antibiotic resistance, emphasizing the urgent need for tailored therapeutic strategies and robust surveillance systems.

Table 1: Antibiotic Resistance Profiles of Key Pathogenic Bacteria.

Bacterial Pathogen	**Type of Resistance**	**Key Resistance Mechanisms**	**Antibiotics Affected**	**References**
Staphylococcus aureus (MRSA)	Methicillin resistance	Altered penicillin-binding protein PBP2a encoded by *mecA*	β-lactams (penicillin, cephalosporins)	[19]
Enterococcus faecium (VRE)	Vancomycin resistance	Altered cell wall precursors	vancomycin	[20]
Escherichia coli	ESBL-mediated resistance	Production of extended-spectrum β-lactamases	Penicillin, third-generation cephalosporins	[21,22]
Klebsiella pneumoniae	Carbapenem resistance	Carbapenemase enzymes	Carbapenems, cephalosporins	[23]
Pseudomonas aeruginosa	Multidrug resistance (MDR)	Efflux pumps, porin loss, β-lactamase production	β-lactams, fluoroquinolones, aminoglycosides	[24]
Mycobacterium tuberculosis	Multidrug resistance (MDR-TB)	Chromosomal mutations in drug targets (*rpoB*, *katG*)	Isoniazid, rifampicin	[25]
Acinetobacter baumannii	Extensive drug resistance (XDR)	Enzymatic degradation, efflux pumps, target site mutations	Carbapenems, aminoglycosides	[26,27]

Neisseria gonorrhoeae	High-level resistance	Target modification and enhanced efflux	Fluoroquinolones, extended-spectrum cephalosporins	[28]
Salmonella enterica	Multidrug resistance	Plasmid-mediated resistance determinants	Ampicillin, chloramphenicol, fluoroquinolones	[29]
Streptococcus pneumoniae	Penicillin resistance	Altered penicillin-binding proteins	β-lactams, macrolides	[30]

2. Global Health and Economic Impact of Antibiotic Resistance

Global health systems and economic stability are increasingly threatened by antibiotic resistance (ABR). The increasing incidence of resistant bacterial pathogens has greatly lowered the effectiveness of current antibiotic therapy, resulting in higher rates of treatment failure, longer sickness, and increased mortality. The scale of bacterial antimicrobial resistance's impact on public health was highlighted by a groundbreaking global investigation that found that it was directly responsible for around 1.27 million deaths in 2019 and contributed to about 5 million deaths overall [31]. ABR makes managing both community-acquired and healthcare-associated infections more difficult from a health systems standpoint. Long-term hospital stays, the use of combination or last-resort antibiotic treatments, and more thorough diagnosis and monitoring processes are frequently necessary for resistant infections. In low- and middle-income countries (LMICs), where access to sophisticated antimicrobials and diagnostic tools is restricted, these factors put further strain on already overburdened healthcare infrastructures [32]. Consequently, ABR exacerbates global health inequities, disproportionately affecting vulnerable populations with limited access to quality healthcare. Antibiotic resistance has equally significant economic repercussions. Resistant infections raise direct medical costs at the microeconomic level because they require more laboratory testing, longer hospital stays, and more expensive medications. Productivity losses brought on by protracted illness, incapacity, and early death are the source of indirect expenses. These cumulative impacts result in lower labor supply, lower household income, and slower economic growth at the macroeconomic level. According to World Bank projections, antimicrobial resistance could lower global GDP by up to 3.8% by 2050 in the absence of effective containment measures, with LMICs suffering the greatest financial losses [33]. Additionally, the sustainability of contemporary medical procedures that significantly depend on efficient antibacterial prophylaxis, such as organ transplantation, chemotherapy, surgery, and neonatal care, is threatened by antibiotic resistance. Decades of medical advancement could be undone if antibiotic efficacy declines, since it raises the danger and expense of these treatments [32]. The economic burden is therefore not limited to infectious disease management but extends across multiple sectors of healthcare delivery. Antibiotic resistance's effects on global health and the economy are consequently intricately linked and reinforce one another. In addition to lowering economic output and escalating global inequality, rising resistance rates also raise morbidity, death, and healthcare expenses.

3. Current Strategies for Control and Prevention of Antibiotic Resistance

Antibiotic resistance (AR), which restricts treatment options and raises morbidity, death, and healthcare costs, has become a significant global public health concern. The effective prevention and treatment of infectious diseases is compromised by antibiotic resistance (AR), a rapidly expanding global public health concern that raises healthcare costs, prolongs illness, and increases mortality [34]. Coordinated tactics targeting the environment, animal health, and human health are being employed globally to address this issue. This review summarizes current strategies for controlling and preventing antibiotic resistance.

3.1 Antimicrobial Stewardship Programs (ASPs)

Coordinated treatments known as antimicrobial stewardship programs (ASPs) aim to maximize the use of antibiotics in order to enhance patient outcomes, lower adverse effects, and prevent the evolution of resistance [35]. The goal of antimicrobial stewardship programs is to optimize the use of antibiotics by promoting the appropriate selection of medication, dosage, route of administration, and duration of treatment. Research has shown that well-executed ASPs can dramatically lower hospital-acquired infections brought on by multidrug-resistant organisms (MDRs) and incorrect antibiotic administration [36].

3.2 Infection Prevention and Control Measures

Limiting the spread of resistant infections in healthcare and community settings requires effective infection prevention and control (IPC) methods. Hand hygiene, isolation measures, cleaning and disinfection of the surroundings, and immunization campaigns are some strategies. It has been demonstrated that IPC and stewardship initiatives work in concert to lower resistance rates and the frequency of infections linked to healthcare [37].

3.3 Rational Use of Antibiotics in Human Medicine

In order to reduce the establishment of resistance, rational prescribing methods are essential. This entails giving antibiotics only when necessary, choosing narrow-spectrum medications whenever feasible, maximizing dosage and duration, and teaching patients about adherence. Misuse, including self-medication and over-the-counter availability, makes resistance worse, especially in low- and middle-income countries (LMICs) [5].

3.4 Surveillance and Monitoring of Antibiotic Resistance

Antibiotic resistance surveillance and monitoring are crucial for identifying patterns of resistance, directing clinical care, and influencing public health regulations. Early identification of new threats is made possible by international programs like the World Health Organization's Global Antimicrobial Resistance Surveillance System (GLASS), which offers standardized data on important bacterial diseases and their resistance profiles [38]. By providing localized insights, assisting with epidemic response, and assessing the results of stewardship initiatives, national and regional programs help international effort [39]. Strategies to lessen the public health burden of antibiotic resistance are strengthened when traditional surveillance is combined with molecular and genomic technologies to improve the ability to detect transmission channels and forecast resistance evolution [5].

3.5 Regulation of Antibiotic Use in Agriculture and Animal Husbandry

Non-therapeutic and prophylactic use of antibiotics in livestock and aquaculture contributes significantly to the spread of resistance to humans through the food chain and environment [40]. Regulatory measures, including banning growth-promoting antibiotics, restricting prophylactic use, and enforcing prescription-only access, have been implemented in several countries with demonstrable reductions in resistant bacteria in animals and humans [41].

3.6 Research and Development of New Therapeutics

New antibiotics and other therapeutic strategies, including bacteriophage therapy, antimicrobial peptides, and anti-virulence drugs, require ongoing research. The discovery of new drug targets and resistance-modulating pathways has been made possible by recent developments in genomics, bioinformatics, and high-throughput screening technology. The use of artificial intelligence-assisted platforms and structure-based drug design is growing in order to optimize antibacterial drugs with improved selectivity and less vulnerability to resistance development. Rapid diagnostic tool development also makes tailored therapy possible, reducing needless antibiotic exposure.

3.7 One Health Approach

Antibiotic resistance is a complicated, multifaceted issue that affects human, animal, and environmental health, according to the One Health concept. In order to stop the emergence and spread of resistant infections, it highlights coordinated efforts across different domains. One Health programs offer a comprehensive framework for reducing resistance by combining surveillance, stewardship, and infection control in people, animals, and wildlife [42]. The method also emphasizes how environmental reservoirs, such as antibiotic-contaminated soil and water, contribute to the spread of resistance genes [43]. It has been demonstrated that collaborative initiatives under the One Health paradigm are more effective than standalone interventions in a single sector at improving policy-making, optimizing the use of antibiotics, and lowering the global burden of antibiotic resistance.

4. Emerging Alternative Therapeutic Approaches

The emergence of antimicrobial resistance (AMR) threatens to render common infections untreatable, posing enormous clinical and economic costs around the world. Traditional antibiotics, while powerful, are becoming more ineffective due to bacterial adaptability and horizontal gene transfer. As a result, there is an urgent need for novel therapeutic techniques that either overcome resistance mechanisms or improve the efficacy of existing medications. This study summarizes current achievements in non-traditional approaches for controlling AMR.

4.1 Bacteriophage therapy

One of the most promising substitutes for traditional antibiotics is still bacteriophage (phage) therapy. Phages are viruses that minimize damage to the host microbiota by selectively infecting and lysing bacteria. Enhancing phage efficacy through adaptive evolution, co-therapy with antibiotics, and designing phages to expand host range and circumvent bacterial resistance mechanisms are examples of recent tactics. Phage therapy has proven effective against

multidrug-resistant (MDR) microorganisms in both clinical and compassionate use scenarios, in addition to laboratory investigations [44]. Recent developments include engineered phages that improve host range and delivery, and modular phage structures for antibiotic delivery. For example, self-assembling T7 phage syringes loaded with penicillin have shown efficacy against β-lactam-resistant Escherichia coli, highlighting innovative delivery systems that bypass classical resistance mechanisms [45].

4.2 Combination and synergistic therapies

Therapeutic efficacy is increased, and the risk of resistance development is decreased when conventional antibiotics are combined with unconventional agents like phages, antimicrobial peptides (AMPs), or nanomaterials. Combination therapy limits adaptive resistance by concurrently targeting microorganisms through several methods [46]. Phage-nanomaterial platforms and nanotechnology-optimized delivery systems are innovative methods to enhance drug penetration into biofilms and MDR bacteria.

4.3 Antimicrobial peptides (AMPs)

Antimicrobial peptides are naturally occurring or manufactured compounds that usually damage bacterial membranes or intracellular activities. AMPs have broad-spectrum efficacy against bacteria, fungi, and viruses, making them excellent choices for resistant illnesses [47]. Because of their broad-spectrum efficacy and low tendency to cause resistance, AMPs are becoming powerful antimicrobial agents. These peptides interfere with essential cellular functions or damage bacterial cell membranes. In order to find peptides with improved specificity and less cytotoxicity, current research makes use of synthetic AMPs and AI-assisted design. Their potential is seen in both direct antibacterial action and synergistic effects that boost the efficacy of currently available antibiotics.

4.4 Probiotics and Immunomodulators

Probiotic therapies use live beneficial microorganisms or their metabolites to balance the host microbiota and prevent pathogenic colonization. Probiotics can compete with infections, alter host immune responses, and restore disrupted microbial ecosystems caused by antibiotic usage [48]. Probiotics, by restoring healthy microbiota dynamics, may help to combat resistant infections indirectly. These strategies are being tested as complements to traditional treatments to reduce pathogen burden and prevent opportunistic infections.

4.5 Anti-virulence and targeted protein inhibition

Antivirulence and targeted protein inhibition techniques offer intriguing alternatives to conventional antibiotics since they disarm pathogens rather than suppressing their growth, lowering selective pressure for resistance development. These methods target bacterial virulence factors like toxins, adhesion molecules, secretion systems, and quorum sensing pathways, which are required for host colonization and disease development but not for bacterial survival [49,50]. Furthermore, targeted protein inhibition can disrupt bacterial regulatory and stress-response pathways involved in mutation generation and adaptive evolution, effectively slowing the emergence of antibiotic resistance and extending the life of existing antimicrobials [51]. Although obstacles such as pathogen specificity and reliance on

host immune clearance persist, antivirulence and evolution-informed medicines provide a strategic framework for treating multidrug-resistant diseases while conserving the host microbiota.

4.6 Nanoparticles and Novel Delivery System

Nanoparticle (NP)-based techniques use designed particles to transport antimicrobial drugs, provide direct antimicrobial effects, or improve host targeting. Nanoparticles, which are usually between 1 and 100 nanometers in size, have special physicochemical characteristics that allow them to interact with bacterial cells differently than conventional antibiotics. Metallic nanoparticles (e.g., silver and zinc oxide) can damage bacterial membranes and produce reactive oxygen species, whereas nanocarriers can increase medication administration and biofilm penetration [52]. By facilitating regulated medication release and better penetration into bacterial cells, polymeric and lipid-based nanoparticles further improve antibacterial activity. The possibility of bacteria becoming resistant to nanoparticles is greatly decreased because they act through several sites at once. Nanomedicine advancements include photothermal and photodynamic therapies that kill bacteria with light-activated NPs, as well as nanocarriers that precisely target resistant bacteria. The use of nanotechnology offers promise in resolving phage resistance and biofilm issues in MDR species.

Novel drug delivery technologies are critical in increasing the efficacy of antimicrobial therapy by optimizing drug delivery to infected locations. Antibiotics can be encapsulated by liposomes, solid lipid nanoparticles, and polymeric nanocarriers to increase their bioavailability and prevent degradation. By enabling tailored and prolonged drug delivery, these systems lessen systemic toxicity and the selective pressure that promotes the emergence of resistance. Therapeutic accuracy is further improved by stimuli-responsive delivery systems, which release antibiotics in reaction to pH shifts, enzyme activity, or other infection-specific circumstances. The capacity of nanoparticles and innovative delivery methods to fight bacterial biofilms, which are extremely resistant to traditional antibiotics, is one of their biggest benefits. Nanoparticles have the ability to deliver large concentrations of antimicrobial drugs directly to embedded bacteria, break down extracellular polymeric materials, and penetrate biofilm matrices. Because biofilms are frequently involved in chronic infections and device-associated illnesses, they are very useful in treating these conditions. The therapeutic use of nanoparticles and innovative drug delivery methods faces a number of obstacles despite their great potential. Toxicity, long-term safety, environmental effect, large-scale manufacturing, and regulatory approval are still major challenges. However, research is still being done to overcome these constraints by creating nanomaterials that are both biocompatible and biodegradable [53,54].

4.7 Antibiotic Adjuvants and Resistance Modulators

Antibiotic adjuvants and resistance modulators are a promising technique for increasing the efficiency of existing antibiotics by targeting bacterial resistance mechanisms rather than killing the pathogen directly. Efflux pump inhibitors (EPIs) are particularly important because they block multidrug efflux systems such as RND, MFS, and ABC transporters, raising intracellular antibiotic concentrations and resensitizing resistant bacteria. β-lactamase inhibitors, such as clavulanic acid, tazobactam, sulbactam, and novel non-β-lactam inhibitors like avibactam, shield β-lactam

antibiotics against enzymatic breakdown and broaden their antibacterial spectrum. Furthermore, membrane permeabilizers, such as polymyxins and antimicrobial peptides, damage the integrity of bacterial outer membranes, particularly in Gram-negative bacteria, allowing for greater antibiotic uptake. Furthermore, metabolic pathway blockers work by inhibiting important bacterial metabolic processes like folate synthesis, energy production, and cell wall precursor pathways, weakening bacterial defenses and synergistically increasing antibiotic action. Collectively, these adjuvants minimize selective pressure for resistance development while maximizing the therapeutic duration of existing antibiotics, making them useful components of combination therapy against multidrug-resistant diseases [55,56].

4.8 CRISPR-Cas–Based Antimicrobials

CRISPR-Cas-based antimicrobials are a highly precise and unique antibacterial technique that uses programmable nucleases to specifically target and eradicate antibiotic-resistant bacteria. This technique targets resistance genes, such as β-lactamases or efflux pumps, to destroy resistance determinants or selectively kill resistant organisms while preserving susceptible and beneficial microbiota. CRISPR-guided bacterial killing is often accomplished by inducing double-stranded breaks in critical chromosomal genes or resistance- conferring plasmids, resulting in irreversible DNA damage and cell death. Advanced delivery techniques, including bacteriophage-derived vectors (phagemids), conjugative plasmids, and customized nanoparticles, enable the targeted transfer of CRISPR-Cas components into bacterial cells, ensuring the technology's effectiveness. Despite its promise, various limits and biosafety concerns remain, including delivery efficiency in complex microbial communities, potential off-target effects, horizontal gene transfer hazards, and ethical and regulatory issues involved with environmental discharge. Nonetheless, CRISPR-Cas antimicrobials provide a revolutionary platform for precision antimicrobial therapy and resistance management [57,58].

5. Future Prospects

Antibiotic resistance is still a dynamic, ever-evolving worldwide problem that necessitates continued scientific research and coordinated international action. Future attempts to combat antibiotic resistance are expected to focus on a multimodal approach that combines state-of-the-art research, improved medical procedures, and effective policy implementation. One of the most exciting prospects is the development of novel antibiotics with unique mechanisms of action that can effectively circumvent existing resistance pathways. Advances in genetics, bioinformatics, and artificial intelligence will probably accelerate drug discovery by enabling the identification of new bacterial targets and the optimization of antimicrobial medications. Antibiotic resistance management will require a comprehensive and forward-thinking plan that includes scientific innovation, legislative reform, and global collaboration. Advances in genetics, artificial intelligence, and high-throughput screening are predicted to speed up the discovery of new antimicrobial drugs and optimize drug design while reducing resistance development. Precision medical approaches, aided by quick testing technologies, will enable tailored therapy while reducing unnecessary antibiotic exposure. Investigating and using new therapeutic strategies that put less selective pressure on bacterial populations than traditional antibiotics is a key component of future therapy. Promising alternative and adjunct medicines, such as

bacteriophage therapy, antimicrobial peptides, antivirulence drugs, microbiome-based interventions, and immunomodulators, provides potential opportunities to supplement or replace conventional antibiotics. Strengthening antimicrobial stewardship, expanding global surveillance networks, and implementing strict antibiotic usage laws in human health, agriculture, and the environment will remain critical to resistance management. Furthermore, the One Health approach, which acknowledges the interconnection of human, animal, and environmental health, is predicted to play a critical role in preventing the emergence and spread of resistant infections. Long-term investment in research, international cooperation, and evidence-based policy implementation will be critical to maintaining antibiotic efficacy and protecting global public health.

6. Conclusion

Antibiotic resistance is rapidly spreading and poses a significant threat to modern healthcare systems around the world. Bacterial adaptability, fueled by genetic plasticity and selective pressure from prolonged antibiotic treatment, has resulted in the widespread development of multidrug-resistant infections. This growing opposition not only jeopardizes clinical outcomes but also imposes high socioeconomic costs and threatens the long-term viability of modern medical procedures. To effectively mitigate antibiotic resistance, a comprehensive and coordinated approach is required. Optimizing antimicrobial use through stewardship programs, establishing infection prevention and surveillance systems, and enforcing antibiotic use restrictions in both human and animal health are critical components of resistance management. Equally crucial is the resuscitation of antimicrobial research and development, particularly the investigation of novel therapeutic techniques that lessen selective pressure on bacterial populations. The One Health concept provides a unifying framework for understanding the linked roles of humans, animals, and the environment in the emergence and dissemination of resistance. Antibiotic resistance necessitates immediate and ongoing global action, backed by strong scientific evidence, policy commitment, and public participation. Without prompt action, the ongoing loss of antibiotic efficacy threatens to undo medical progress and endanger global health security.

References

1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *P T*. 2015;40(4):277-283.
2. Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev*. 2010;74(3):417-433. doi:10.1128/MMBR.00016-10
3. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0
4. Chambers HF, DeLeo FR. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nat Rev Microbiol*. 2009;7(9):629-641. doi:10.1038/nrmicro2200
5. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. *Lancet Infect Dis*. 2013;13(12):1057-1098. doi:10.1016/S1473-3099(13)70318-9

6. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x
7. Tacconelli E, Carrara E, Savoldi A, et al; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis*. 2018;18(3):318-327. doi:10.1016/S1473-3099(17)30753-3
8. D'Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. *Nature*. 2011;477(7365):457-461. doi:10.1038/nature10388
9. Fleming A. On the antibacterial action of cultures of a *Penicillium*, with special reference to their use in the isolation of *B. influenzae*. *Br J Exp Pathol*. 1929;10(3):226-236.
10. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. *Nature*. 1940;146(3713):837. doi:10.1038/146837a0
11. Watanabe T. Infective heredity of multiple drug resistance in bacteria. *Bacteriol Rev*. 1963;27(1):87-115.
12. Jevons MP. "Celbenin"-resistant staphylococci. *Br Med J*. 1961;1(5219):124-125.
13. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. *Nat Med*. 2004;10(12 suppl):S122-S129. doi:10.1038/nm1145
14. Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors: an overview. *Cold Spring Harb Perspect Med*. 2016;6(8):a025247. doi:10.1101/cshperspect.a025247
15. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol*. 2015;13(1):42-51. doi:10.1038/nrmicro3380
16. Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin Microbiol Rev*. 2015;28(2):337-418. doi:10.1128/CMR.00117-14
17. Delcour AH. Outer membrane permeability and antibiotic resistance. *Biochim Biophys Acta*. 2009;1794(5):808-816. doi:10.1016/j.bbapap.2008.11.005
18. von Wintersdorff CJH, Penders J, van Niekerk JM, et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. *Front Microbiol*. 2016;7:173. doi:10.3389/fmicb.2016.00173
19. Lade H, Kim JS. Molecular determinants of β-lactam resistance in methicillin-resistant *Staphylococcus aureus* (MRSA): an updated review. *Antibiotics (Basel)*. 2023;12(9):1362. doi:10.3390/antibiotics12091362
20. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. *Nat Rev Microbiol*. 2012;10(4):266-278. doi:10.1038/nrmicro2761
21. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. *Clin Microbiol Rev*. 2005;18(4):657-686. doi:10.1128/CMR.18.4.657-686.2005
22. Ibrahim DR, Dodd CE, Stekel DJ, et al. Multidrug-resistant ESBL-producing *Escherichia coli* in clinical samples from the UK. *Antibiotics (Basel)*. 2023;12(1):169. doi:10.3390/antibiotics12010169

23. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis*. 2011;17(10):1791-1798. doi:10.3201/eid1710.110655
24. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of resistance mechanisms. *Clin Microbiol Rev*. 2009;22(4):582-610. doi:10.1128/CMR.00040-09
25. Ravibalan T, Maruthai K, Samrot AV, Muthaiah M. Characterization of *katG* and *rpoB* gene mutations in multidrug-resistant *Mycobacterium tuberculosis* clinical isolates. *Int J Curr Microbiol App Sci*. 2014;3(9):1072-1080.
26. Martínez-Trejo A, Ruiz-Ruiz JM, Gonzalez-Avila LU, et al. Evasion of antimicrobial activity in *Acinetobacter baumannii* by target site modifications. *Int J Mol Sci*. 2022;23(12):6582. doi:10.3390/ijms23126582
27. Abdi SN, Ghotaslou R, Ganbarov K, et al. *Acinetobacter baumannii* efflux pumps and antibiotic resistance. *Infect Drug Resist*. 2020;13:423-434. doi:10.2147/IDR.S228514
28. Unemo M, Shafer WM. Antimicrobial resistance in *Neisseria gonorrhoeae*. *Clin Microbiol Rev*. 2014;27(3):587-613. doi:10.1128/CMR.00058-13
29. Eng SK, Pusparajah P, Ab Mutalib NS, et al. *Salmonella*: a review on pathogenesis, epidemiology and antibiotic resistance. *Front Life Sci*. 2015;8(3):284-293. doi:10.1080/21553769.2015.1051243
30. Dowson CG, Hutchison A, Woodford N, et al. Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of *Streptococcus pneumoniae*. *Proc Natl Acad Sci U S A*. 1990;87(15):5858-5862. doi:10.1073/pnas.87.15.5858
31. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0
32. World Health Organization. *Global Action Plan on Antimicrobial Resistance: Progress Report*. World Health Organization; 2023.
33. World Bank. *Drug-Resistant Infections: A Threat to Our Economic Future*. World Bank Group; 2016.
34. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog Glob Health*. 2015;109(7):309-318. doi:10.1179/2047773215Y.0000000030
35. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and *Clostridioides difficile* infection: a systematic review and meta-analysis. *Lancet Infect Dis*. 2017;17(9):990-1001. doi:10.1016/S1473-3099(17)30325-2
36. Dyar OJ, Huttner B, Schouten J, Pulcini C; ESGAP (ESCMID Study Group for Antimicrobial Stewardship). What is antimicrobial stewardship? *Clin Microbiol Infect*. 2017;23(11):793-798. doi:10.1016/j.cmi.2017.08.026
37. Haque M, Sartelli M, McKimm J, Abu Bakar M. Health care-associated infections – an overview. *Infect Drug Resist*. 2018;11:2321-2333. doi:10.2147/IDR.S177247
38. World Health Organization. *Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2020*. World Health Organization; 2020.

39. Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis*. 2019;19(1):56-66. doi:10.1016/S1473-3099(18)30605-4
40. Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. *Clin Microbiol Rev*. 2011;24(4):718-733. doi:10.1128/CMR.00002-11
41. Van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in food animals. *Proc Natl Acad Sci U S A*. 2015;112(18):5649-5654. doi:10.1073/pnas.1503141112
42. Robinson TP, Bu DP, Carrique-Mas J, et al. Antibiotic resistance is the quintessential One Health issue. *Trans R Soc Trop Med Hyg*. 2016;110(7):377-380. doi:10.1093/trstmh/trw048
43. Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in humans, livestock and the wider environment. *Philos Trans R Soc Lond B Biol Sci*. 2015;370(1670):20140083. doi:10.1098/rstb.2014.0083
44. Girma A. Bacteriophages as an alternative strategy for the treatment of drug-resistant bacterial infections. *Cell Surf*. 2025;14:100149. doi:10.1016/j.tcsw.2024.100149
45. Shim H. Self-assembling T7 phage syringes with modular genomes for targeted delivery of penicillin against beta-lactam-resistant *Escherichia coli*. arXiv. 2024. Preprint. arXiv:2401.xxxxx.
46. Kaspute G, Zebrauskas A, Streckyte A, Ivaskiene T, Prentice U. Combining advanced therapies with alternative treatments to manage antimicrobial resistance. *Pharmaceutics*. 2025;17(5):648. doi:10.3390/pharmaceutics17050648
47. Wensley L. Alternative therapies in the era of antibiotic resistance. *J Anc Dis Prev Remedies*. 2024;12(5):1-2.
48. Elshaghabee FFF, Rokana N. Mitigation of antibiotic resistance using probiotics, prebiotics and synbiotics. *Environ Chem Lett*. 2022;20(2):1295-1308. doi:10.1007/s10311-021-01342-0
49. Mühlen S, Dersch P. Anti-virulence strategies to target bacterial infections. In: *How to Overcome the Antibiotic Crisis*. Springer; 2016:147-183. doi:10.1007/978-3-319-49242-3_7
50. Dehbanipour R, Ghalavand Z. Anti-virulence therapeutic strategies against bacterial infections. *Germs*. 2022;12(2):262-275. doi:10.18683/germs.2022.1337
51. Merrikh H, Kohli RM. Targeting evolution to inhibit antibiotic resistance. *FEBS J*. 2020;287(20):4341-4353. doi:10.1111/febs.15329
52. Joshi DC, Chavan MB, Tiwari SW, Devi S. Advances in combating antimicrobial resistance in MRSA. *Antonie Van Leeuwenhoek*. 2025;118(12):xxxx. doi:10.1007/s10482-025-01999-x
53. Ferreira M, Ogren M, Dias JNR, et al. Liposomes as antibiotic delivery systems: a promising nanotechnological strategy against antimicrobial resistance. *Molecules*. 2021;26(7):2047. doi:10.3390/molecules26072047
54. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. *Adv Drug Deliv Rev*. 2013;65(13-14):1803-1815. doi:10.1016/j.addr.2013.07.011

55. Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. *Trends Microbiol*. 2016;24(11):862-871. doi:10.1016/j.tim.2016.06.009
56. Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. *Trends Biotechnol*. 2013;31(3):177-184. doi:10.1016/j.tibtech.2012.12.006
57. Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nat Biotechnol*. 2014;32(11):1146-1150. doi:10.1038/nbt.3043
58. Pursey E, Sünderhauf D, Gaze WH, Westra ER, van Houte S. CRISPR-Cas antimicrobials: challenges and future prospects. *PLoS Pathog*. 2018;14(6):e1006990. doi:10.1371/journal.ppat.1006990

rebioin journal OF BIOSCIENCES

Fighting Superbugs: Understanding Resistance, Shaping the Future.





Plot no 977, GMS Road, near Balliwala Flyover, opposite Cubic Plaza, Dehradun, Uttarakhand 248001

admin@reboin.com

www.rebioin.com